1763 Stock Overview
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China.
No risks detected for 1763 from our risk checks.
China Isotope & Radiation Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$17.70|
|52 Week High||HK$32.10|
|52 Week Low||HK$17.04|
|1 Month Change||-8.67%|
|3 Month Change||-19.55%|
|1 Year Change||-44.34%|
|3 Year Change||-3.91%|
|5 Year Change||n/a|
|Change since IPO||-11.94%|
Recent News & Updates
Is There Now An Opportunity In China Isotope & Radiation Corporation (HKG:1763)?
While China Isotope & Radiation Corporation ( HKG:1763 ) might not be the most widely known stock at the moment, it saw...
|1763||HK Medical Equipment||HK Market|
Return vs Industry: 1763 exceeded the Hong Kong Medical Equipment industry which returned -60.3% over the past year.
Return vs Market: 1763 underperformed the Hong Kong Market which returned -23.3% over the past year.
|1763 Average Weekly Movement||5.4%|
|Medical Equipment Industry Average Movement||9.1%|
|Market Average Movement||7.0%|
|10% most volatile stocks in HK Market||13.8%|
|10% least volatile stocks in HK Market||3.3%|
Stable Share Price: 1763 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 1763's weekly volatility (5%) has been stable over the past year.
About the Company
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Independent Clinical Medical and Laboratory Services, and Other Business. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals; UBT kits and analyzers; and in vitro immunoassay diagnostic reagents and kits.
China Isotope & Radiation Fundamentals Summary
|1763 fundamental statistics|
Is 1763 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1763 income statement (TTM)|
|Cost of Revenue||CN¥1.90b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||1.05|
|Net Profit Margin||6.53%|
How did 1763 perform over the long term?See historical performance and comparison
2.5%Current Dividend Yield
Is 1763 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1763?
Other financial metrics that can be useful for relative valuation.
|What is 1763's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 1763's PE Ratio compare to its peers?
|1763 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: 1763 is good value based on its Price-To-Earnings Ratio (14.4x) compared to the peer average (142.4x).
Price to Earnings Ratio vs Industry
How does 1763's PE Ratio compare vs other companies in the Medical Equipment Industry?
Price-To-Earnings vs Industry: 1763 is good value based on its Price-To-Earnings Ratio (14.4x) compared to the Hong Kong Medical Equipment industry average (17.1x)
Price to Earnings Ratio vs Fair Ratio
What is 1763's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||14.4x|
|Fair PE Ratio||12.6x|
Price-To-Earnings vs Fair Ratio: 1763 is expensive based on its Price-To-Earnings Ratio (14.4x) compared to the estimated Fair Price-To-Earnings Ratio (12.6x).
Share Price vs Fair Value
What is the Fair Price of 1763 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1763 (HK$17.7) is trading below our estimate of fair value (HK$26.59)
Significantly Below Fair Value: 1763 is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: 1763 is good value based on its PEG Ratio (1x)
Discover undervalued companies
How is China Isotope & Radiation forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1763's forecast earnings growth (14.5% per year) is above the savings rate (1.5%).
Earnings vs Market: 1763's earnings (14.5% per year) are forecast to grow slower than the Hong Kong market (17% per year).
High Growth Earnings: 1763's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1763's revenue (14.3% per year) is forecast to grow faster than the Hong Kong market (10.3% per year).
High Growth Revenue: 1763's revenue (14.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1763's Return on Equity is forecast to be low in 3 years time (10.3%).
Discover growth companies
How has China Isotope & Radiation performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1763 has high quality earnings.
Growing Profit Margin: 1763's current net profit margins (6.5%) are higher than last year (5%).
Past Earnings Growth Analysis
Earnings Trend: 1763's earnings have declined by 1.9% per year over the past 5 years.
Accelerating Growth: 1763's earnings growth over the past year (57.2%) exceeds its 5-year average (-1.9% per year).
Earnings vs Industry: 1763 earnings growth over the past year (57.2%) exceeded the Medical Equipment industry 35.4%.
Return on Equity
High ROE: 1763's Return on Equity (11.2%) is considered low.
Discover strong past performing companies
How is China Isotope & Radiation's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 1763's short term assets (CN¥6.7B) exceed its short term liabilities (CN¥4.0B).
Long Term Liabilities: 1763's short term assets (CN¥6.7B) exceed its long term liabilities (CN¥470.9M).
Debt to Equity History and Analysis
Debt Level: 1763 has more cash than its total debt.
Reducing Debt: 1763's debt to equity ratio has reduced from 32.5% to 12.6% over the past 5 years.
Debt Coverage: 1763's debt is well covered by operating cash flow (104.1%).
Interest Coverage: 1763's interest payments on its debt are well covered by EBIT (243.7x coverage).
Discover healthy companies
What is China Isotope & Radiation current dividend yield, its reliability and sustainability?
Dividend Score 1/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 1763's dividend (2.47%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.74%).
High Dividend: 1763's dividend (2.47%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.89%).
Stability and Growth of Payments
Stable Dividend: 1763 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 1763's dividend payments have increased, but the company has only paid a dividend for 4 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (36%), 1763's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (32.5%), 1763's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
China Isotope & Radiation has no CEO, or we have no data on them.
Experienced Board: 1763's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
China Isotope & Radiation Corporation's employee growth, exchange listings and data sources
- Name: China Isotope & Radiation Corporation
- Ticker: 1763
- Exchange: SEHK
- Founded: 1983
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: HK$5.662b
- Shares outstanding: 319.87m
- Website: https://www.circ.com.cn
Number of Employees
- China Isotope & Radiation Corporation
- No. 66 Changwa Middle Street
- Haidian District
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.